U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.

CNS Activity

Curator's Comment: Polymyxin B penetrates BBB and cause neurotoxic effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q28824
Gene ID: 338037.0
Gene Symbol: MYLK
Target Organism: Bos taurus (Bovine)
70.0 µM [IC50]
Target ID: Protein kinase C (Bos taurus)
4.0 µM [IC50]
800.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
PubMed

PubMed

TitleDatePubMed
LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E.
1949 Sep
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008 Oct
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008 Oct
Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.
2015 Nov 13
A feed-forward loop between SroC and MgrR small RNAs modulates the expression of eptB and the susceptibility to polymyxin B in Salmonella Typhimurium.
2016 Nov
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 25,000 to 30,000 units/kg/day (Intramuscular injection), 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks (Intrathecal injection).
15,000 to 25,000 units/kg body weight/day
Route of Administration: Intravenous
Polymyxin B MICs were determined for different strains of P. aeruginosa in Ca-MHB using a broth macrodilution method. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 35°C in ambient air. The polymyxin B MIC ranged from 0.5 to 1 mg/liter.
Substance Class Mixture
Created
by admin
on Fri Dec 15 15:51:09 GMT 2023
Edited
by admin
on Fri Dec 15 15:51:09 GMT 2023
Record UNII
J2VZ07J96K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POLYMYXIN B
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
POLYMYXIN B [VANDF]
Common Name English
polymyxin b [INN]
Common Name English
Polymyxin b [WHO-DD]
Common Name English
POLYMYXIN B [MI]
Common Name English
POLYSPORIN COMPONENT POLYMYXIN B
Brand Name English
POLYMIXIN B
Common Name English
Classification Tree Code System Code
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QA07AA05
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS03AA03
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS01AA18
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S03AA03
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC J01XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QJ01XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC A07AA05
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.155
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S02AA11
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS02AA11
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000175499
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 333.120
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1484E
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1445
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1662B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S01AA18
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.960
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NCI_THESAURUS C78160
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1484H
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QJ51XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.154
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
Code System Code Type Description
DAILYMED
J2VZ07J96K
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
MESH
D011112
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048467
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-768-4
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
WIKIPEDIA
POLYMYXIN B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
EVMPD
SUB03937MIG
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
FDA UNII
J2VZ07J96K
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
CAS
1404-26-8
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
MERCK INDEX
m8963
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00781
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
NCI_THESAURUS
C61894
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
RXCUI
8536
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
4246
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
INN
490
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
LACTMED
Polymyxin B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201283
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Definition References